Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Non-Current Liabilities: 2023-2024

  • Contineum Therapeutics' Total Non-Current Liabilities was N/A to $6.3 million in Q1 2024 from the same period last year, while for Mar 2024 it was $6.3 million, marking a year-over-year change of. This contributed to the annual value of $5.6 million for FY2023, which is N/A change from last year.
  • According to the latest figures from Q1 2024, Contineum Therapeutics' Total Non-Current Liabilities is $6.3 million, which was up 13.47% from $5.6 million recorded in Q4 2023.
  • Contineum Therapeutics' 5-year Total Non-Current Liabilities high stood at $6.3 million for Q1 2024, and its period low was $5.6 million during Q4 2023.
  • For the 2-year period, Contineum Therapeutics' Total Non-Current Liabilities averaged around $6.0 million, with its median value being $6.0 million (2023).